www.horizonscan.nl gebruikt cookies om het gebruik van de website te analyseren en het gebruiksgemak te verbeteren. Lees meer over
cookies
op www.rijkshuisstijl.nl
Sluiten
You are here:
Horizonscan geneesmiddelen
Medicines
Search the site
Search
Neurological disorders
All latest versions
6 June 2023
7 December 2022
7 June 2022
7 December 2021
8 June 2021
8 December 2020
10 June 2020
10 December 2019
12 June 2019
13 December 2018
12 June 2018
9 January 2018
Compact view
Extended view
Grouped by indication
Grouped by status
Grouped by reason of inclusion in Horizonscan Geneesmiddelen
Grouped by submission date
Grouped by expected registration date
Grouped by manufacturer
Grouped by mechanism of action
Grouped by particularity
Grouped by registration phase
Grouped by publication date
Ungrouped
Filters
Sluit
Registration
Show ATMPs only
Show Orphan drugs only
Mechanism of action
Any mechanism of action
Unknown
Alkylating agent
Allergen
Allogeneic modified cell therapy
Amino acid
Anesthetic
Angiogenesis inhibitor
Antiandrogen
Antibiotic
Antibody-drug conjugate
Anticoagulant
Antifungals
Antihistamine
Antioxidant
Antisense oligonucleotide
Autologous modified cell therapy
Bcl-2 inhibitor
BET inhibitor
Calcineurin inhibitor
Cancer vaccine
Cannabinoid
CAR-T therapy
CDK4 / 6 tyrosine kinase inhibitor
CFS1R inhibitor
CGRP-directed antibody
Chelating agent
Coagulant
Combination therapy
Complement inhibitor
Corticosteroid
CTLA-4 antibody
Cytostatic
Disinfectant
Enzyme
Enzyme inhibitor
Enzyme replacement therapy
Gene therapy
GLP-1 receptor agonist
Glucagon analogue
Growth factor
HIV inhibitor
Hormonal therapy
Immunostimulation
Immunosuppression
Insulin preparation
Interferon inhibitor
Interleukin inhibitor
Ion channel blocker
JAK tyrosine kinase inhibitor
LABA / ICS
LABA / LAMA
LABA / LAMA / ICS
LAMA
MEK kinase inhibitor
Neurotoxin
Neurotransmitter
Oncolytic adenovirus
Other
Other, see general comments
PARP inhibitor
PD-1 / PD-L1 inhibitor
Proteasome inhibitor
Protein chaperone
Receptor agonist
Receptor antagonist
Serine / threonine kinase inhibitor
SGLT inhibitor
Small interfering RNA (siRNA)
Sodium channel blocker
Thrombin inhibitor
TNF-alpha inhibitor
Tyrosine kinase inhibitor
Vasodilator
Virus inhibitor
Budgetting framework
Any budgetting framework
Unknown
Extramural (GVS)
Intermural (MSZ)
Particularity
Any particularity
Unknown
New medicine with Priority Medicines (PRIME)
New therapeutical formulation
Reason of inclusion
New medicines
Indication extensions
IND
Biosimilars / generics
BS
G
Download
ADHD
Lisdexamfetamine
IND
Melatonine
ALS
Masitinib
Sodium phenylbutyrate / ursodoxicoltaurine
Tofersen
IND
Dementia
Blarcamesine
Donanemab
Hydromethylthionine mesylaat
Lecanemab
Depression
Agomelatine
IND
Bupropion / dextromethorphan
Duchenne
Fordadistrogene movaparvovec
Givinostat
Golodirsen
Losmapimod
Vamorolone
Viltolarsen
Epilepsy
Cannabidiol
IND
Fenfluramine
IND
Ganaxolone
Eye disorders
Aflibercept
Diabetic macular edema
BS
Eylea is indicated in preterm infants for the treatment of retinopathy of prematurity (ROP) with zone I (stage 1+, 2+, 3 or 3+), zone II (stage 2+ or 3+) or AP-ROP (aggressive posterior ROP) disease.
IND
Avacincaptad pegol
Bevacizumab-vikg
Bimatoprost
Botaretigene sparoparvovec
Faricimab
Treatment of neovascular (wet) age-related macular degeneration (nAMD).
Treatment of visual impairment due to diabetic macular oedema (DME).
Laruparetigene zosaparvovec
Lenadogene nolparvovec
Pegcetacoplan
IND
Perfluorohexyloctane
Phentolamine
Polihexanide
Ranibizumab
Treatment of neovascular age-related macular degeneration (AMD)
Wet age-related macular degeneration (AMD)
BS
Reproxalap
Sepofarsen
Varenicline
Headache
Atogepant
Dihydroergotamine
Eptinezumab
Lasmiditan
Meloxicam / rizatriptan
Rimegepant
Acute treatment of migraine with or without aura in adults
Preventive treatment of episodic migraine in adults who have at least 4 migraine attacks per month
Multiple sclerosis
Natalizumab
BS
Ublituximab
Muscular diseases other
Bidridistrogene xeboparvovec
Dantroleen
G
Daxibotulinumtoxine A
Deoxythymidine / deoxycytidine
Di-deuterated ethyl linoleate
Eculizumab
Extension of indication to include treatment of paediatric patients aged 6 to less than 18 years with acetylcholine receptor-antibody (AChR-Ab) positive (+) refractory gMG.
IND
Extension of indication to include treatment of paediatric patients with refractory generalised myasthenia gravis (gMG).
IND
Efgartigimod
Omaveloxolone
Ravulizumab
IND
Rozanolixizumab
Satralizumab
IND
Zilucoplan
Neurological disorders other
Cannabidiol
Clazosentan
Eladocagene exuparvovec
Human normal immunoglobulin
IND
Inebilizumab
Ravulizumab
IND
Tiratricol
Tominersen
Trofinetide
Troriluzole
Vutrisiran
Other psychiatry
Dexmedetomidine
Pain
Bupivacaine
IND
Buprenorfine
IND
Difluprednate
Fasinumab
Parkinson's
Levodopa / carbidopa
SMA
Risdiplam
5q SMA in patients 2 months of age and older, with a clinical diagnosis of Type 1, Type 2 or Type 3 SMA or with one to four SMN2 copies.
Extension of indication to include treatment of patients below 2 months of age.
IND
Schizophrenia, psychosis, bipolar disorder
Roluperidon
Ulotaront
Sleep disorders
Daridorexant
Natriumoxybaat controlled release
Pitolisant
IND
Unknown
Eplontersen
Naar boven
National Health Care Institute
Login
Understanding of expected market entry
of innovative medicines
Service
Contact
Downloads
Export
About this site
Copyright
Privacy
Cookies
Toegankelijkheid
Kwetsbaarheid melden
About the Horizon Scan
Nederlands
English